COAG is Hemab Therapeutics Holdings, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $44.70. Market cap: $2.09B.
Stock snapshot
| Price | $44.70 |
| Market cap | $2.09B |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
About COAG
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Related non-dividend companies
Other non-dividend stocks investors research alongside COAG. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is COAG's current stock price?
COAG (Hemab Therapeutics Holdings, Inc.) is currently trading at $44.70.
Does COAG pay a dividend?
COAG (Hemab Therapeutics Holdings, Inc.) does not currently pay a regular dividend.
Track COAG in DiviDrip
Add COAG to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search COAG and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.